Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TMDX

TMDX - TransMedics Group Inc Stock Price, Fair Value and News

$123.54+2.23 (+1.84%)
Delayed

78/100

TMDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

78/100

TMDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TMDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TMDX Price Action

Last 7 days

-4.7%

Last 30 days

-7.3%

Last 90 days

-2.6%

Trailing 12 Months

92.0%

TMDX RSI Chart

TMDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TMDX Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

22.27

Price/Sales (Trailing)

7

EV/EBITDA

28.89

Price/Free Cashflow

31.72

TMDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TMDX Fundamentals

TMDX Revenue

Revenue (TTM)

605.5M

Rev. Growth (Yr)

32.18%

Rev. Growth (Qtr)

11.78%

TMDX Earnings

Earnings (TTM)

190.3M

Earnings Growth (Yr)

1.4K%

Earnings Growth (Qtr)

333.34%

TMDX Profitability

Operating Margin

59.92%

EBT Margin

17.76%

Return on Equity

40.22%

Return on Assets

17.81%

Free Cashflow Yield

3.15%

TMDX Investor Care

Shares Dilution (1Y)

1.90%

Diluted EPS (TTM)

4.87

TMDX Alerts

  • 5 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025488.2M531.3M566.4M605.5M
2024296.9M358.8M401.1M441.5M
2023119.1M151.1M191.8M241.6M
202239.1M51.4M71.8M93.5M
202125.2M29.9M28.2M30.3M
202026.5M24.2M24.1M25.6M
201915.2M17.9M21.1M23.6M
201800013.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About TransMedics Group Inc

TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
 CEO
 WEBSITEtransmedics.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES212

TransMedics Group Inc Frequently Asked Questions

TMDX is the stock ticker symbol of TransMedics Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of TransMedics Group Inc is 4.24 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, TMDX's PE ratio (Price to Earnings) is 22.27 and Price to Sales (PS) ratio is 7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMDX PE ratio will change depending on the future growth rate expectations of investors.